These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20035540)

  • 1. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.
    Kim JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Lee KH; Lee SH; Kim SJ
    J Surg Oncol; 2010 Feb; 101(2):149-55. PubMed ID: 20035540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
    Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE
    Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
    de Bree E; Rosing H; Filis D; Romanos J; Melisssourgaki M; Daskalakis M; Pilatou M; Sanidas E; Taflampas P; Kalbakis K; Beijnen JH; Tsiftsis DD
    Ann Surg Oncol; 2008 Apr; 15(4):1183-92. PubMed ID: 18239973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study.
    Pomel C; Ferron G; Lorimier G; Rey A; Lhomme C; Classe JM; Bereder JM; Quenet F; Meeus P; Marchal F; Morice P; Elias D
    Eur J Surg Oncol; 2010 Jun; 36(6):589-93. PubMed ID: 20466507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
    Helm CW
    Oncologist; 2009 Jul; 14(7):683-94. PubMed ID: 19608639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
    J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: a case control study.
    Benedetti Panici P; Palaia I; Graziano M; Bellati F; Manci N; Angioli R
    Oncology; 2010; 78(1):20-5. PubMed ID: 20185937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.
    Muñoz-Casares FC; Rufián S; Arjona-Sánchez Á; Rubio MJ; Díaz R; Casado Á; Naranjo Á; Díaz-Iglesias CJ; Ortega R; Muñoz-Villanueva MC; Muntané J; Aranda E
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):267-74. PubMed ID: 21499894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended follow-up.
    Skinner EN; Boruta DM; Gehrig PA; Boggess JF; Fowler WC; Van Le L
    Gynecol Oncol; 2005 Jul; 98(1):59-62. PubMed ID: 15913741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
    Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
    J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from appendix: preliminary results of a survival analysis.
    Marcotte E; Sideris L; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Dubé P
    Ann Surg Oncol; 2008 Oct; 15(10):2701-8. PubMed ID: 18654822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer.
    Ryu KS; Kim JH; Ko HS; Kim JW; Ahn WS; Park YG; Kim SJ; Lee JM
    Gynecol Oncol; 2004 Aug; 94(2):325-32. PubMed ID: 15297169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
    Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
    Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
    Di Giorgio A; Naticchioni E; Biacchi D; Sibio S; Accarpio F; Rocco M; Tarquini S; Di Seri M; Ciardi A; Montruccoli D; Sammartino P
    Cancer; 2008 Jul; 113(2):315-25. PubMed ID: 18473354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
    Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
    Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.